Buscar en
Revista Iberoamericana de Micología
Toda la web
Inicio Revista Iberoamericana de Micología Therapies against murine Candida guilliermondii infection, relationship between ...
Información de la revista
Vol. 32. Núm. 1.
Páginas 34-39 (Enero - Marzo 2015)
Descargar PDF
Más opciones de artículo
Vol. 32. Núm. 1.
Páginas 34-39 (Enero - Marzo 2015)
Original article
DOI: 10.1016/j.riam.2013.10.008
Acceso a texto completo
Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome
Terapia antifúngica frente a la infección por Candida guilliermondii en ratones, correlación entre los parámetros farmacodinámicos in vitro y la eficacia in vivo
Katihuska Paredesa, Francisco Javier Pastora, Javier Capillaa,
Autor para correspondencia
, Deanna A. Suttonc, Emilio Mayayob, Annette W. Fothergillc, Josep Guarroa
a Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain
b Unitat de Anatomia Patològica, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain
c Fungus Testing Laboratory, University of Texas Health Science Center, San Antonio, TX, USA
Este artículo ha recibido
Información del artículo
Texto completo
Descargar PDF
Figuras (5)
Mostrar másMostrar menos

Candida guilliermondii has been recognized as an emerging pathogen showing a decreased susceptibility to fluconazole and considerably high echinocandin MICs.


Evaluate the in vitro activity of anidulafungin in comparison to amphotericin B and fluconazole against different isolates of C. guilliermondii, and their efficacy in an immunosuppressed murine model of disseminated infection.


The in vitro susceptibility of four strains against amphotericin B, fluconazole and anidulafungin was performed by using a reference broth microdilution method and time-kill curves. The in vivo efficacy was evaluated by determination of fungal load reduction in kidneys of infected animals receiving deoxycholate AMB at 0,8mg/kg i.v., liposomal amphotericin B at 10mg/kg i.v., fluconazole at 50mg/kg, or anidulafungin at 10mg/kg.


Amphotericin B and anidulafungin showed fungicidal activity, while fluconazole was fungistatic for all the strains. In the murine model, liposomal amphotericin B at 10mg/kg/day was effective in reducing the tissue burden in kidneys of mice infected with any of the tested strains. However, amphotericin B, anidulafungin and fluconazole were only effective against those strains showing low MIC values.


Liposomal amphotericin B showed the higher activity and efficacy against the two strains of C. guilliermondii, in contrast to the poor effect of fluconazole and anidulafungin. Further studies with more isolates of C. guilliermondii representing a wider range of MICs should be carried out to assess whether there is any relationship between MIC values and anidulafungin efficacy.

Candida guilliermondii
Animal model
Fungal infection

Candida guilliermondii es un patógeno emergente, con reducida sensibilidad al fluconazol y a las equinocandinas.


Evaluar la actividad in vitro de la anidulafungina, en comparación con la de la anfotericina B y el fluconazol, frente a C. guilliermondii y su eficacia en un modelo animal de infección diseminada.


La sensibilidad in vitro se valoró mediante microdilución en caldo y curvas de mortalidad. La eficacia in vivo se evaluó mediante la determinación de la carga fúngica en riñón de ratones inmunosuprimidos con infección diseminada por C. guilliermondii tratados con anfotericina B desoxicolato (0.8mg/kg i.v.), anfotericina B liposomal (10mg/kg i.v.), fluconazol (50mg/kg) o anidulafungina (10mg/kg).


La anfotericina B y la anidulafungina mostraron actividad fungicida, mientras que el fluconazol fue fungistático frente a todas las cepas. En el modelo murino, la anfotericina B liposomal redujo para todas las cepas la carga fúngica en riñones, mientras que la anfotericina B desoxicolato, la anidulafungina y el fluconazol fueron efectivas solo en aquellos animales infectados con las cepas de menor valor de concentración mínima inhibitoria (CMI).


La anfotericina B liposomal mostró la mayor actividad y eficacia frente a C. guilliermondii, en contraste con el limitado efecto del fluconazol y de la anidulafungina. Se necesitan estudios que incluyan cepas con un rango más amplio de CMI que permitan determinar la relación entre la actividad in vitro y la eficacia de la anidulafungina.

Palabras clave:
Candida guilliermondii
Modelo animal
Infección fúngica
Texto completo

The fungus Candida guilliermondii is widely distributed in nature, including the human microbiota of the skin and mucosal surfaces.22 Although this species shows a reduced virulence in comparison to other Candida species,3 it is currently considered an emerging pathogen, with a major incidence in Latin America.18C. guilliermondii has been recognized as the etiologic agent of a wide variety of clinical infections, including disseminated ones mainly in immunocompromised patients,22 and nosocomial outbreaks in surgical patients with intravascular devices.13 Currently, the recommended treatment for invasive candidiasis in neutropenic patients includes caspofungin (CFG) or micafungin (MFG) as first-line therapies, liposomal amphotericin B (LAMB) and anidulafungin (AFG) being alternatives, while fluconazole (FLC) is recommended only when susceptibility to this drug is confirmed.23 However, several studies have shown that C. guilliermondii has a decreased susceptibility to FLC8,15,19, and therapeutic failures associated with isolates with high amphotericin B (AMB) minimal inhibitory concentrations (MICs) have been reported.9,12,24 Although nearly 90% of isolates shows echinocandins MICs equal or lower than clinical breakpoints (CBP) of susceptibility (2μg/ml),17 similar to other species of Candida, such as C. parapsilosis, some isolates of C. guilliermondii show MICs considerably high.8,15 Available data concerning the AFG efficacy in invasive candidiasis are limited and the potential role of that drug in the clinical practice is poorly known.23 In this context, animal studies can play an important role for a better understanding of the in vitro–in vivo correlation.11 Therefore, our main objective was to evaluate the in vitro and in vivo activities of AFG against different isolates of C. guilliermondii, comparing the results with those of AMB and FLC.

Materials and methodsFungal isolates

Four clinical isolates of C. guilliermondii (UTHSC 11-142, UTHSC 10-499, UTHSC 11-685 and UTHSC 10-3207) were used in the in vitro study and two of them (UTHSC 11-685 and UTHSC 11-142) were selected for the murine model on the basis of their different in vitro susceptibilities. The isolates were identified by sequencing the internal transcribed spacer (ITS) region and the D1–D2 domains of the rRNA, comparing the sequences with those of the type strain of this species.

In vitro studies

The in vitro susceptibility of the four strains to AMB, FLC and AFG was evaluated using a reference broth microdilution method,6Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 being included as quality controls.

Time-kill curves were developed for all the strains according to previous studies.5,20 In brief, a stock solution of each antifungal was prepared, AMB (Sigma–Aldrich Co., St. Louis, USA) and AFG (Pfizer Inc., Madrid, Spain) were dissolved in dimethyl sulfoxide and FLC (Pfizer Inc., Madrid, Spain) in distilled water. Further, drug dilutions were prepared in 9ml of standard RPMI 1640 medium to obtain concentrations of 0.03, 0.12, 0.5, 1, 2, 8 and 32μg/ml of each drug. The isolates were subcultured at 35°C for 24h on potato dextrose agar (PDA) plates. Cultures of C. guilliermondii were suspended in sterile saline and the resulting suspensions were adjusted at 5×106 colony forming units (CFU)/ml by haemocytometer counts and by serial plating onto PDA to confirm viability. Dilutions and controls (drug-free) were inoculated with 1ml of the fungal suspensions, resulting in a starting inoculum of 5×105CFU/ml, and incubated at 35°C. An aliquot of 100μl from each tube was collected at 0, 2, 4, 6, 8, 24, and 48h after inoculation and diluted in distilled water; 30 μl of them were cultured onto PDA plates and incubated at 35°C for 48h for CFU/ml determination. A CFU decrease of ≥99.9% or 3 log10 unit compared to starting inoculum was considered fungicidal, while a reduction of <99.9% or <3log10 unit, was considered fungistatic. The limit of detection was 50CFU/ml. All time-kill curve studies were performed in duplicate.

In vivo studies

Male OF-1 mice (Charles River; Criffa SA, Barcelona, Spain) with a mean weight of 30g were used in the experiment. Mice were housed in standard boxes with free access to food and water. All animal procedures were supervised and approved by the Universitat Rovira i Virgili Animal Welfare and Ethics Committee.

Mice were rendered neutropenic one day prior to infection by an intraperitoneal (i.p.) injection of 200mg/kg of cyclophosphamide (Genoxal; Laboratorios Funk SA, Barcelona, Spain) plus an intravenous (i.v.) injection of 5-fluorouracil (Fluorouracilo; Ferrer Farma SA, Barcelona, Spain) at 150mg/kg.10,14 The day of infection, mice were challenged i.v. with 1×108CFU/animal of each of the two strains of C. guilliermondii, UTHSC 11-685 and UTHSC 11-142, in 0.2ml of sterile saline into the lateral tail vein.3,4

Groups of eight animals were randomly established for each strain and drug. The groups were treated as follows: amphotericin B deoxycholate (AMBd) (Xalabarder Pharmacy, Barcelona, Spain) at doses of 0.8mg/kg i.v. once a day (QD); liposomal amphotericin B (LAMB) (Gilead Sciences S.A., Madrid, Spain) at 10mg/kg i.v., QD; FLC (Pfizer Inc., Madrid, Spain) at 25mg/kg orally (p.o.) by gavage, twice daily (BID); and AFG (Ecalta; Pfizer Ltd., Sandwich, Kent, United Kingdom) at 10mg/kg of body weight/dose i.p., QD. All treatments began 24h after challenge, and lasted for 7 days. Controls received no treatment. To prevent bacterial infections, all mice received 5mg/kg day ceftazidime subcutaneously from days 1 to 7 after infection. Mice were checked daily and were euthanized on day 8 post-infection by CO2 anoxia. The efficacy of each drug was evaluated by tissue burden reduction and histopathological studies. Kidneys were aseptically removed, and one of them was weighed and homogenized in 2ml of sterile saline. Serial 10-fold dilutions of the homogenates were plated onto PDA and incubated for 48h at 35°C for CFU/g calculation. For the histopathology study the remaining kidney was fixed with 10% buffered formalin, dehydrated, paraffin embedded, and sliced into 2μm sections, which were stained with hematoxylin–eosin (H-E) and periodic acid-Schiff (PAS) stain for examination by light microscopy.


Colony counts from tissue were analyzed using the Mann–Whitney U-test, using Graph Pad Prism 4.0 for Windows (GraphPad Software, San Diego, CA, USA). When P values were below 0.05 the differences were considered statistically significant.

ResultsIn vitro studies

MICs of AMB were 0.25–1μg/ml, 0.06–0.25μg/ml for AFG and 0.5–1μg/ml for FLC. Following the cut-offs of susceptibility for AMB, FLC and AFG against C. guilliermondii,16 all isolates were susceptible to the three drugs. Quality control strains susceptibilities were within the accepted ranges.6

The killing kinetics of AMB showed a fast fungicidal activity that increased with drug concentration. At concentrations equivalent to the MIC, that drug showed a fungicidal effect against three of the four isolates tested (Fig. 1). This activity started immediately after inoculation at concentrations over 1μg/ml, the fungicidal endpoint being reached after 4h at 32μg/ml. AFG at concentrations above 0.5μg/ml showed fungicidal activity starting after 4h of incubation. The fungicidal endpoint was reached at 12–24h of incubation at 32μg/ml (Fig. 2). FLC showed fungistatic activity against all four isolates (Fig. 3).

Fig. 1.

Time-killing kinetics assays of AMB against four strains of C. guilliermondii. (■) 0.03μg/ml, (▴) 0.12μg/ml, (□) 0.5μg/ml, (○) 1μg/ml, (Δ) 2μg/ml, (▿) 8μg/ml, (♦) 32μg/ml, (●) control. Dashed lines represent a CFU decrease of 3log10 units in growth compared with the initial inoculum (fungicidal activity), dotted lines indicate the quantification limit of the test.

Fig. 2.

Time-killing kinetics assays of AFG against four strains of C. guilliermondii. (■) 0.03μg/ml, (▴) 0.12μg/ml, (□) 0.5μg/ml, (○) 1μg/ml, (Δ) 2μg/ml, (▿) 8μg/ml, (♦) 32μg/ml, (●) control. Dashed lines represent a CFU decrease of 3 log10 units in growth compared with the initial inoculum (fungicidal activity), dotted lines indicate the quantification limit of the test.

Fig. 3.

Time-killing kinetics assays of FLC against four strains of C. guilliermondii. (■) 0.03μg/mL, (▴) 0.12μg/ml, (□) 0.5μg/ml, (●) 1μg/ml, (Δ) 2μg/ml, (▿)8μg/ml, (♦) 32μg/ml, (●) control. Dashed lines represent a CFU decrease of 3log10 units in growth compared with the initial inoculum (fungicidal activity), dotted lines indicate the quantification limit of the test.

In vivo studies

LAMB at 10mg/kg was the only drug able to reduce the fungal load in kidneys of mice infected with each of the two strains, being the reduction significantly higher than that of the other therapies (P0.04). AMBd and FLC were only able to reduce the tissue burden in mice infected with the strain that showed the lowest MICs for these two drugs, i.e., 0.25μg/ml for AMB and 0.5μg/ml for FLC (P0.008). In the case of AFG the fungal load reduction was modest and lower than that for AMBd, and it significantly reduced the tissue burden in kidney only with respect to control group for strain UTHSC 11-685 (P=0.002) (Fig. 4).

Fig. 4.

Effects of antifungal treatment on colony counts of C. guilliermondii in kidney of neutropenic mice, 8 days post infection. LAMB 10, liposomal amphotericin B at 10mg/kg QD; AMBd 0.8, amphotericin B deoxycholate at 0.8mg/kg QD; AFG 10, anidulafungin at 10mg/kg QD. aP<0.05 versus control; bP<0.05 versus AMBd 0.8, AFG 10 and FLC 50; cP<0.05 versus AFG 10 and FLC 50.


The histological study showed focal infiltration of fungal cells in kidneys of untreated animals and in mice treated with AMBd, FLC or AFG. Kidneys of mice treated with LAMB showed only a mild fungal invasion. Signs of necrosis, inflammatory response or parenchyma alterations were nor observed in controls neither in treated animals (Fig. 5).

Fig. 5.

Presence of fungal infiltration (black arrow) in the kidney section of a control mouse infected with C. guilliermondii, at 8 days post infection (periodic acid Schiff staining, magnification 1000×). Bar=10μm.


The in vitro studies did not reveal decreased susceptibility of C. guilliermondii isolates to FLC or AFG. In agreement with previous studies, time-kill curves of AMB showed a concentration-dependent fungicidal activity against all the isolates,4,5,7 and FLC showed a fungistatic effect regardless of the concentration tested.7 It is known that AMBd exhibits a higher efficacy than its lipidic formulation, especially in kidney, when administered both at the same doses.1 However, pharmacokinetic studies showed that after the administration of 0.75mg/kg of AMBd the Cmax of AMB attained in mice serum was 0.30μg/ml.25 However, the AMB MIC of one of the two isolates tested is higher than this value; therefore, we used a high dose of LAMB in order to reach higher concentrations.1 Indeed, the administration of LAMB at 10mg/kg was effective in reducing the fungal load of both strains. This fact correlated with killing curves, where AMB achieved its fungicidal activity against the two isolates tested in vivo, at concentrations of 1μg/ml. To our knowledge, this is the first study that tried to establish a relationship between the killing kinetics and the in vivo experimental efficacy of AFG and FLC against clinical isolates of C. guilliermondii. Only a previous study on echinocandins exists, particularly on caspofungin (CFG) in disseminated infection by C. guilliermondii. CFG at 1mg/kg was effective in reducing the kidney fungal load in mice infected with one strain of C. guilliermondii with a MIC of 8μg/ml, while time killing revealed that no fungicidal activity was achieved at concentrations of 64μg/ml.4 Conversely, our study showed a concentration-dependent activity of AFG, which at 32μg/ml exerted a fungicidal activity, as previously reported,17 at 24h and at 8μg/ml. Previous studies reported AFG concentrations in serum and kidney of approximately 13μg/ml after 7 days of treatment at doses of 10mg/kg.21 Here, AFG was able to reduce only modestly the fungal burden in kidneys of neutropenic mice infected with one of the two strains tested, which does not seem to be related with the low AFG MICs difference between the two strains tested (1 dilution), suggesting that the response to AFG treatment is strain dependent. Similarly, FLC was also only able to reduce slightly the fungal burden in kidney of mice challenged with one of the two strains in spite of the dose administrated which reach serum concentrations above the MICs,2 which was also not surprising due to its fungistatic activity.

In conclusion, our study showed the higher activity and efficacy of LAMB against the two strains of C. guilliermondii, in contrast to the poor effect of FLC and AFG. However, further studies with more isolates of C. guilliermondii representing a wider range of AFG MICs should be carried out to assess if any relationship between MIC values and AFG efficacy exists.

Conflict of interest

None to declare.

D. Andes, N. Safdar, K. Marchillo, R. Conklin.
Pharmacokinetic–pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Antimicrob Agents Chemother, 50 (2006), pp. 674-684
D. Andes, M. van Ogtrop.
Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
Antimicrob Agents Chemother, 43 (1999), pp. 2116-2120
M. Arendrup, T. Horn, N. Frimodt-Møller.
In vivo pathogenicity of eight medically relevant Candida species in an animal model.
Infection, 30 (2002), pp. 286-291
F. Barchiesi, E. Spreghini, S. Tomassetti, A. Della Vittoria, D. Arzeni, E. Manso, et al.
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
Antimicrob Agents Chemother, 50 (2006), pp. 2719-2727
E. Cantón, J. Pemán, M. Sastre, M. Romero, A. Espinel-Ingroff.
Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.
Antimicrob Agents Chemother, 50 (2006), pp. 2829-2832
Clinical Laboratory Standards Institute.
Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A3.
3rd ed., CLSI, (2008),
G. Di Bonaventura, I. Spedicato, C. Picciani, D. D’Antonio, R. Piccolomini.
In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Antimicrob Agents Chemother, 48 (2004), pp. 4453-4456
D.J. Diekema, S.A. Messer, L.B. Boyken, R.J. Hollis, J. Kroeger, S. Tendolkar, et al.
In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.
J Clin Microbiol, 47 (2009), pp. 3170-3177
J.D. Dick, B.R. Rosengard, W.G. Merz, R.K. Stuart, G.M. Hutchins, R. Saral.
Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii.
Ann Intern Med, 102 (1985), pp. 67-68
J.R. Graybill, R. Bocanegra, L.K. Najvar, D. Loebenberg, M.F. Luther.
Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression.
Antimicrob Agents Chemother, 42 (1998), pp. 2467-2473
J. Guarro.
Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi.
J Antimicrob Chemother, 66 (2011), pp. 1447-1466
G. Kovacicova, J. Hanzen, M. Pisarcikova, D. Sejnova, J. Horn, R. Babela, et al.
Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors.
J Infect Chemother, 7 (2001), pp. 45-48
L. Masala, R. Luzzati, L. Maccacaro, L. Antozzi, E. Concia, R. Fontana.
Nosocomial cluster of Candida guilliermondii fungemia in surgical patients.
Eur J Clin Microbiol Infect Dis, 22 (2003), pp. 686-688
M.J. Ortoneda, J. Capilla, F.J. Pastor, J. Guarro.
Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis.
Diagn Microbiol Infect Dis, 50 (2004), pp. 247-251
M.A. Pfaller, M. Castanheira, D.J. Diekema, S.A. Messer, R.N. Jones.
Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida.
J Clin Microbiol, 49 (2011), pp. 3800-3804
M.A. Pfaller, D.J. Diekema.
Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012.
J Clin Microbiol, 50 (2012), pp. 2846-2856
M.A. Pfaller, D.J. Diekema, D. Andes, M.C. Arendrup, S.D. Brown, S.R. Lockhart, CLSI Subcommittee for Antifungal Testing, et al.
Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Drug Resist Updat, 14 (2011), pp. 164-176
M.A. Pfaller, D.J. Diekema, D.L. Gibbs, V.A. Newell, D. Ellis, V. Tullio, Global Antifungal Surveillance Group, et al.
Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.
J Clin Microbiol, 48 (2010), pp. 1366-1377
M.A. Pfaller, D.J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S.C. Chang, Global Antifungal Surveillance Group, et al.
Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
J Clin Microbiol, 44 (2006), pp. 3551-3556
M.A. Pfaller, D.J. Sheehan, J.H. Rex.
Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.
Clin Microb Rev, 17 (2004), pp. 268-280
V. Salas, F.J. Pastor, E. Calvo, E. Mayayo, G. Quindós, A.J. Carillo, et al.
Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: in vitro activity, (1→3)-beta-d-glucan and mannan serum levels, histopathological findings, and in vivo efficacy.
Antimicrob Agents Chemoter, 55 (2011), pp. 4985-4989
V. Savini, C. Catavitello, D. Onofrillo, G. Masciarelli, D. Astolfi, A. Balbinot, et al.
What do we know about Candida guilliermondii? A voyage throughout past and current literature about this emerging yeast.
A.J. Ullmann, M. Akova, R. Herbrecht, C. Viscoli, M.C. Arendrup, S. Arikan-Akdagli, ESCMID Fungal Infection Study Group, et al.
ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).
Clin Microbiol Infect, 18 (2012), pp. 53-67
J.A. Vazquez, T. Lundstrom, L. Dembry, P. Chandrasekar, D. Boikov, M.B. Parri, et al.
Invasive Candida guilliermondii infection: in vitro susceptibility studies and molecular analysis.
Bone Marrow Transplant, 16 (1995), pp. 849-853
N.P. Wiederhold, V.H. Tam, J. Chi, R.A. Prince, D.P. Kontoyiannis, R.E. Lewis.
Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis.
Antimicrob Agents Chemother, 50 (2006), pp. 469-473
Copyright © 2013. Revista Iberoamericana de Micología
Opciones de artículo
es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.